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Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that regulates 
fibrinolysis, cell adhesion and cell motility via its interactions with plasminogen activators and 
vitronectin. PAI-1 has been shown to play a role in a number of diverse pathologies including 
cardiovascular diseases, obesity and cancer and is therefore an attractive therapeutic target. However 
the multiple patho-physiological roles of PAI-1, and understanding the relative contributions of these 
in any one disease setting, make the development of therapeutically relevant molecules challenging. 
Here we describe the identification and characterisation of fully human antibody MEDI-579, which binds 
with high affinity and specificity to the active form of human PAI-1. MEDI-579 specifically inhibits serine 
protease interactions with PAI-1 while conserving vitronectin binding. Crystallographic analysis reveals 
that this specificity is achieved through direct binding of MEDI-579 Fab to the reactive centre loop (RCL) 
of PAI-1 and at the same exosite used by both tissue and urokinase plasminogen activators (tPA and 
uPA). We propose that MEDI-579 acts by directly competing with proteases for RCL binding and as such 
is able to modulate the interaction of PAI-1 with tPA and uPA in a way not previously described for a 
human PAI-1 inhibitor.
Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily1 
and is an important therapeutic target for coronary thrombosis, as well as fibrotic diseases and many cancers2,3. 
The major physiological role of PAI-1 is to block the conversion of plasminogen to plasmin by tissue-type plas-
minogen activator (tPA) and urokinase-type plasminogen activator (uPA)4. PAI-1 is also a key modulator of 
cell adhesion and motility through blocking vitronectin binding to integrins5, a function wholly independent of 
its protease inhibition role6. Crystal structures of PAI-1 in complex with uPA7, tPA8 and vitronectin9 have been 
solved, revealing that these interactions occur in spatially distinct parts of the molecule.
PAI-1 exhibits profound conformational plasticity with native (or active), latent and cleaved conformations 
reported (Fig. 1a), and an additional ‘substrate’ conformation proposed10–13. PAI-1 is synthesised in the active 
conformation, which is characterised by the accessibility of its reactive centre loop (RCL) to protease binding12,14. 
The RCL (designated P17 to P3′) includes a ‘bait’ peptide bond (P1-P1′) that mimics the normal substrate of 
the target proteases13. The number after ‘P’ indicates the position of the residue N-terminal to the scissile bond; 
the prime indicates residues C-terminal to the scissile bond. Interaction of this bait region with the active site of 
either tPA or uPA in a 1:1 stoichiometric complex results in cleavage of the P1-P1′ bond and extensive structural 
re-arrangement, characterised by the insertion of the N-terminal portion of the RCL into β-sheet A and the 
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complete translocation of the protease to the opposite pole of the PAI-1 molecule (Fig. 1b). The PAI-1:protease 
complex is stable and results in both the inhibition of protease and the inactivation of PAI-1. PAI-1 can also act as 
a substrate if protease translocation is slowed by the binding of certain ligands11,15.
PAI-1 is unique amongst the serpins because of its ready conversion from the native to the latent state. 
The half-life of native PAI-1 is approximately 2 hours at 37 °C in vitro, and is slightly longer in vivo due to the 
high-affinity association with the somatomedin domain of vitronectin. Inhibitory activity is dependent on the 
exposure of the RCL in the native state, so the latent form is unable to inhibit proteases. The P1-P1′ bond is also 
inaccessible to proteolytic attack in the latent conformation12.
Figure 1. Structural forms of PAI-1 and the serpin mechanism of protease inhibition: (a) PAI-1 is a 
conformationally labile protein and can rapidly transition from the native (left, 3pb17) to the latent (middle, 
1lj5) state. Ribbon diagrams are shown coloured from N-to-C terminus (blue to red). Conversion to the latent 
state involves incorporation of the RCL (loop at top) into β-sheet A (front sheet) and the extension of strand 1 of 
β-sheet C (s1C). As with most serpins, as similar conformation is obtained upon cleavage within the RCL (right, 
3cvm58). (b) Mechanism of protease inhibition by PAI-1 depicted using PDB structures 5brr8 (tPA:PAI-1) and 
1ezx59 (anti-trypsin:trypsin). The elements of PAI-1 responsible for protease inhibition are the RCL (yellow, with 
P1 Arg depicted as sticks) and β-sheet A (red). After recognition of the RCL by a protease (magenta, centre), the 
protease is irreversibly translocated to the opposite pole of PAI-1 and trapped as a covalent complex (right).
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Work with both neutralising antibodies and small molecule inhibitors have elucidated multiple mechanisms 
of action for the prevention of the initial non-covalent Michaelis-Menton complex formation between PAI-1 and 
its target serine proteases. Two of these mechanisms are irreversible: the accelerated conversion of active PAI-1 to 
latent and the conversion of active PAI-1 to a substrate form16–18. Both these mechanisms act by altering the kinet-
ics of RCL insertion19,20. A reversible mechanism of action has also been described, which involves modulation 
of RCL conformation to prevent serine protease binding21. In addition, inhibitors that prevent Michaelis-Menton 
complex formation may also inhibit or affect the kinetics of PAI-1 binding to vitronectin22. The key to developing 
therapeutic compounds is to understand the specific mechanism of action by the investigational drug on the 
target within a particular disease setting. However, despite a wealth of in vitro characterisation on selective PAI-1 
inhibitors, there is a deficiency in the reporting of in vivo data to link the relevance of mechanistic findings to real 
pharmacological effects. This is often due to a lack of rodent cross-reactivity, or impaired binding to endogenous 
glycosylated PAI-123.
Epitope mapping of PAI-1 antibody inhibitors is a crucial step towards linking specific molecular mechanisms 
of PAI-1 blockade with in vivo pharmacology. Neutralising PAI-1 antibody epitopes have been derived by alanine 
scanning22, the use of chimeric proteins24 or by combining in silico docking with site-directed mutagenesis25. To 
date, no crystal structure of PAI-1 in complex with an inhibitory antibody has been reported. The multiple struc-
tural conformations that PAI-1 can adopt, and the inherent flexibility and short half-life of the active form pose 
challenges to X-ray crystallography.
Here we describe the in vitro and in vivo characterisation of neutralising anti-PAI-1 antibody MEDI-579 and 
the crystal structure of MEDI-579 Fab in complex with human PAI-1. The structure explains the unique charac-
teristics of MEDI-579: inhibition of PAI-1 anti-protease activity but not vitronectin binding; specificity for active 
compared to latent PAI-1; and rodent PAI-1 cross-reactivity. The cross-species reactivity of MEDI-579 enabled 
the specific contribution of PAI-1 anti-protease activity to be characterised in a disease-relevant model of fibrosis. 
Our data directly combine the first structural study of a neutralising PAI-1 antibody with its in vivo pharmaco-
logical effects and provides a structural framework for understanding the consequence of specific blockade of 
protease binding.
Results
Generation and in vitro characterisation of recombinant antibody MEDI-579. A panel of neutral-
ising PAI-1 specific, human, rat and mouse cross-reactive antibodies were isolated from a large phagemid–based 
library of single-chain antibody variable fragments (scFv)26,27, by panning on recombinant human and rat PAI-1 
followed by screening in a PAI-1/tPA competition binding assay. A scFv was selected for affinity maturation 
by ribosome display in vitro evolution28,29. Selection cycles were performed using either human PAI-1 alone, 
or by alternating rounds of selection on human and rat PAI-1. High-throughput screens using human and rat 
PAI-1 were run in parallel to identify scFv variants with improved activity across both species. Significant rodent 
cross-reactivity was only achieved when both human and rat antigens were utilised in the selection and screening 
campaign (Supplementary Fig. S1). No human-rat cross-reactive scFvs were isolated from selections on human 
PAI-1 alone. The most potent scFv, Ab167, was able to neutralise recombinant human, rat and mouse PAI-1 
activity in species-relevant tPA-coupled chromogenic assays (Supplementary Fig. S1). To reduce potential immu-
nogenicity during clinical development, four variable heavy (VH) and five variable light (VL) chain framework 
residues were reverted to the corresponding residues from their closest human germline sequences (IGHV1-
69*12 and IGKV1-5*03 for VH and VL chains respectively) to generate MEDI-579 (Fig. 2).
The fully human antibody, MEDI-579 was formatted as both Fab and human IgG1 and subjected to extensive 
characterisation.
To determine if MEDI-579 could bind to the latent form of PAI-1, a competition ELISA experiment was 
conducted. The commercial preparation of latent human PAI-1 was able to efficiently compete with native for 
Figure 2. MEDI-579 sequence. MEDI-579 is shown in alignment with parent sequence and closest human 
germline matches. CDR sequences are boxed. Vernier residues are marked in red above the sequence. Pink 
shading in MEDI-579 represents positions reverted to match closest germline. Yellow shading in MEDI-579 
indicates positions mutated from parent during affinity maturation.
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binding to MEDI-579, but with an apparent 10-fold lower affinity (Supplementary Fig. S2). However, the results 
were also consistent with a ~10% contamination with native PAI-1, perhaps from incomplete conversion to the 
inactive latent form. This was addressed by incubating an excess of MEDI-579 with the latent material and run-
ning the complex on a size exclusion column (Supplementary Fig. S2). Most of the material did not form complex 
with MEDI-579 and eluted as monomeric PAI-1. A small high molecular weight peak contained the rest of the 
PAI-1. Densitometry analysis of an SDS gel revealed that 12.5% of the PAI-1 complexed with MEDI-579, while 
the remaining 87.5% was unable to interact with the antibody. Moreover, this uncomplexed PAI-1 fraction had 
no activity in a thrombin cleavage assay (Supplementary Fig. S2). We concluded that the conversion to latent was 
incomplete and that the competition ELISA results reflected a small but significant contamination with native 
PAI-1.
It has previously been demonstrated that glycosylation can have a profound effect on the inhibitory activity 
of anti-PAI-1 antibodies23. To demonstrate that MEDI-579 is able to inhibit pharmacologically relevant PAI-
1, MEDI-579 IgG1 was tested for functional blockade of endogenous PAI-1 released from TGFβ1-stimulated 
normal human lung fibroblast (NHLF) and mouse lung fibroblast (MLg) cells30. MEDI-579 was able to inhibit 
plasminogen activation by endogenous PAI-1 with pIC50 values of  9.8 ± 0.14 (IC50 10.5 nM) and 8.99 ± 0.12 (IC50 
1.3 nM) in human and mouse assays respectively (Fig. 3a). The level of other endogenous components of these 
species-specific plasminogen systems are undefined in these assays, so IC50 values cannot be compared to give 
relative measures of affinity. MEDI-579 does not block PAI-1 binding to vitronectin (Fig. 3b), demonstrating that 
MEDI-579 specifically acts to prevent protease binding to PAI-1. Competition binding experiments also demon-
strates that MEDI-579 does not interact with other circulating serpins (Supplementary Fig. S3).
Figure 3. In vitro characterization of MEDI-579 (a) TGFβ-1 stimulated fibroblasts produce PAI-1. The ability 
of this endogenously produced PAI-1 to inhibit protease in an assay dependent on the generation of active 
plasmin from exogenously added plasminogen is then measured. Cells with (+PAI-1) or without (-PAI-1) 
TGFβ-1 stimulation represent 0% or 100% plasmin activity respectively. MEDI-579 is able to inhibit PAI-1 
produced from TGFβ-1 treated normal human lung fibroblasts (NHLFs) and mouse lung fibroblasts (MLgs) 
in this assay with pIC50 = 9.8 ± 0.14 (10.5 nM) and 8.99 ± 0.12 (1.3 nM) respectively. Data shown are an 
average of four independent experiments ± s.e.m. (b) MEDI-579 does not block PAI-1 binding to vitronectin. 
Antibody 33B08 enhances conversion of active PAI-1 to the latent form16 and potently inhibits in this assay 
(IC50 = 12.46 ± 0.45 nM; data is average of two experiments ± s.d.).
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The dissociation constant (KD) of MEDI-579 Fab for human PAI-1 was evaluated by BIAcore. MEDI-579 is an 
ultra-high affinity antibody, with an off-rate constant (kd) in the order of 4×10−5 s−1 and a KD of approximately 
6 pM. MEDI-579 Fab also binds rat PAI-1 with high affinity by this method (Table 1; Supplementary Fig. S4).
MEDI-579 treatment inhibits active PAI-1 and prevents the development of proteinuria and 
pathological changes in the kidney in a mouse model of lupus nephritis. MEDI-579 specifically 
inhibits serine proteases binding to PAI-1, while binding to vitronectin is retained. PAI-1 expression is increased 
in animal models of fibrosis31,32 and genetic deletion of PAI-1 has been shown to be protective33–35.
The role for PAI-1 in glomerulonephritis is well established and has been reported to be independent of vit-
ronectin36. We evaluated the ability of MEDI-579 to inhibit PAI-1 in a mouse model of lupus nephritis37 to deter-
mine whether MEDI-579 is able to provide protection from the development of glomerulonephritis.
A single dose of 10 mg/kg MEDI-579 inhibited circulating active PAI-1 and elevated plasmin 48 hours follow-
ing administration in this model (Fig. 4a). Treatment with MEDI-579 for three weeks provided dose-dependent 
protection from the development of proteinuria (Fig. 4b) and decreased urinary sodium output, another measure 
of renal function (Supplementary Fig. S5). This dose-dependent protection of kidney function correlated with 
inhibition of active PAI-1 levels in both plasma and kidney homogenates (Fig. 4b).
MEDI-579/PAI-1 structural determination. The crystal structure of the complex between PAI-1 and 
MEDI-579 Fab was determined by molecular replacement and refined to an R-factor of 22% and an Rfree of 24% 
(Table 2). The asymmetric unit is composed of four PAI-1:Fab complexes, denoted AIE, BJF, CKG and DLH for 
PAI-1 and the light and heavy chains of the Fab, respectively. The complexes are essentially identical, but AIE was 
chosen for analysis due to its lower average B-factors. With the exception of the RCL, the conformation of PAI-1, 
including within the reported vitronectin binding site, is unaltered by its interaction with MEDI-579 Fab with an 
RMSD of 1 Å when compared to uncomplexed native PAI-1 (3q0338). MEDI-579 Fab binds to the ‘top’ of PAI-1 
directly engaging the RCL, including the scissile P1-P1′ residues, and an exosite immediately adjacent to the RCL 
(Fig. 5a,b). The interface buries a total of 1745 Å2, with the majority (60.5%) involving the light chain of the Fab. 
Interactions with the RCL, from P2 to P3′, accounts for 35% of the total buried surface area, with almost all of the 
contacts (91%) involving the Fab heavy chain. The interaction between the heavy chain of the Fab and the RCL of 
PAI-1 is sufficient to explain both the ability of MEDI-579 to inhibit PAI-1-protease interactions and the lack of 
binding to latent PAI-1. However, for the two main targets of PAI-1, uPA and tPA, a conserved exosite adjacent to 
the RCL is also used for recognition. Both uPA and tPA place an Arg residue (Arg37A - chymotrypsin number-
ing) onto a negatively-charge surface on β-sheet C of PAI-1 to make a salt-bridge with Glu212. The MEDI-579 
Fab similarly contacts this site using VL chain residues His31 and Arg66. Therefore, MEDI-579 inhibits PAI-1 
by blocking both the RCL and the exosite region necessary for recognition of its two targets uPA and tPA. The 
overlap of binding sites on PAI-1 is illustrated in Fig. 5c,d. The position of the Fab on PAI-1 is remote from the 
reported vitronectin binding site (Fig. 5c), which is unaltered upon Fab binding. This supports our observation 
that binding to vitronectin is preserved in the presence of MEDI-579 (Fig. 3b)9, although subtle changes in bind-
ing affinity due to allosteric or other effects cannot be ruled out.
The paratope of MEDI-579 is defined by the twenty-five amino acid residues within 4.0 Å of the sixteen amino 
acids of the PAI-1 epitope (Table 3). The paratope includes residues Arg66, Ser67 and Gly68 are within part 
of a light chain framework region that forms an outer loop, distinct from the CDR loops. Two of these resi-
dues, VL Arg66 and Gly68, are Vernier residues and known to be important for antibody structural integrity. 
During affinity maturation, the appearance of an arginine in place of the glycine at position VL66 was linked 
to an increase in rodent cross-reactivity. In the structure, MEDI-579 VL Arg66 forms a stacking interaction 
with human PAI-1 Tyr220, and is predicted to form a salt-bridge with the negatively charged Glu220 present 
at this position in rodent PAI-1 (Supplementary Fig. S6a). This position is one of three sequence differences 
between rodent and human PAI-1 mapped within the epitope (human positions first): Tyr220Glu, Tyr241Phe 
and Glu350Thr. These amino acid substitutions are identical in mouse and rat PAI-1 sequences (Supplementary 
Fig. S6b). The Tyr241Phe substitution would be predicted to have a relatively neutral effect on the binding energy 
of the interface, as the pi-pi stacking interaction with His31 in VL CDR1 observed in the crystal structure would 
be preserved. Glu350 however appears central in a network of polar interactions as it engages charged residues 
from both the heavy and light chains: Arg97 in VH CDR3 and Lys50 in VLCDR2. A Glu350Thr substitution 
at this position would disrupt this network and contribute towards the overall loss in affinity still observed for 
MEDI-579 between human and rodent PAI-1 species (Supplementary Fig. S6c). In support of the key role pre-
dicted for MEDI-579 VL Arg66 in the rodent PAI-1 interaction, it was demonstrated that reversion of Arg66 back 
to Gly66 in Ab167 scFv reduced binding to rat PAI-1 by approximately 300-fold while binding to human PAI-1 
was not significantly altered (Supplementary Fig. S7).
ka (1/Ms) kd (1/s) KD (pM) Replicates
Human PAI-1 7.02E + 06 (±9.70E + 05) 4.18E−05 (±1.52E − 05) 6 (±2) n = 6
Rat PAI-1 7.64E + 06 (±5.21E + 05) 7.97E−04 (±1.76E − 04) 105 (±30) n = 2
Table 1. MEDI-579 affinity data. BIAcore analysis was performed on MEDI-579 Fab binding to recombinant 
PAI-1. Data are averages ± standard deviation of replicates as indicated.
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Discussion
Serpins play a key role in controlling a diverse array of proteolytic pathways central to human health. Members of 
the serpin family are defined by their highly conserved core structure, including the presence in each of a reactive 
centre loop which is used as bait for specific protease capture. Once bound to the bait peptide, the protease/serpin 
complex undergoes a huge conformational change (for review see Huntington, 2011)39. This conformational flex-
ibility makes targeting of serpins for therapeutic effect and understanding the mechanistic and pharmacological 
consequences of serpin inhibition challenging. The central role of PAI-1 in many disease processes makes it an 
attractive target for drug development. However, despite an interest in targeting this serpin, there are no PAI-1 
inhibitors clinically approved in any indication40.
Here, we report the isolation and affinity maturation of a highly potent neutralising antibody to PAI-1 and 
the crystallisation of the PAI-1/MEDI-579 Fab complex. MEDI-579 interactions across the RCL and a key pro-
tease exosite supports a directly competitive mechanism of action for this antibody and rationally explains the 
observed specificity of MEDI-579 for the active conformation of PAI-1, and the specific blockade of protease, but 
not vitronectin, binding. The rodent cross-reactivity that enabled the in vivo pharmacology was achieved through 
a rationally designed antibody engineering, selection and screening cascade. From the paratope analysis enabled 
by the structure, one mutation introduced during optimisation (VL Arg66) can be identified as a key contributor 
Figure 4. MEDI-579 treatment in adenovirus-interferon-alpha accelerated kidney disease in NZBW/F1 mice. 
(a) Plasma levels of active PAI-1 and Plasmin 48 hr following a single dose of either antibody control or MEDI-
579, n = 5 mice/group, shown as group average ± SEM; P = 0.0037 (active PAI-1) and P = 0.0388 (plasmin) 
by unpaired one-tailed t test with Welch’s correction. (b) MEDI-579 dose-dependently reduces urinary total 
protein (normalised to creatinine); *P < 0.05 MEDI-579 (10 mg/kg) compared to antibody control at Wk 
5, Kruskal-Wallis with Dunn’s multiple comparison. PAI-1 levels in kidney homogenates are also shown; 
*P < 0.05 MEDI-579 (10 mg/kg) compared to antibody control (10 mg/kg), Kruskal-Wallis with Dunn’s multiple 
comparison post-tests.
www.nature.com/scientificreports/
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to the significant increase in rodent cross-reactivity observed. This residue is in the light chain outer loop, in a 
framework region not usually targeted for antibody engineering. Our strategy of introducing random mutations 
across the whole V-region and then affinity selection of these libraries by ribosome display using iterative selec-
tion cycles on human and rodent PAI-1 was successful in identifying this key solution to significantly improving 
rodent cross-reactivity. The importance of the heavy chain outer loop in antigen binding is well studied, and is 
reported to account for 1.3% of human antibody-antigen contacts41,42. To our knowledge, this is the first report 
of a light chain outer loop residue being modified during an in vitro affinity maturation campaign to play a direct 
role in antibody function.
In addition to its role as the primary inhibitor of plasminogen activators, PAI-1 also regulates cell migration 
and adhesion through competition with the receptor for cell bound urokinase-type plasminogen activator (uPAR) 
and integrin αVβ3 for vitronectin binding5,43. To better realise the therapeutic potential of PAI-1 blockade, it is 
important to understand the relative contribution of these two pathways in each disease setting. Studies reported 
to define the contribution of vitronectin and/or protease binding roles of PAI-1 in fibrotic or angiogenic disease 
pathways have been limited to the administration of recombinant mutant PAI-1 molecules44–46, which may be 
impacted by the presence of endogenous PAI-1 or challenges in administering PAI-1 at physiologically relevant 
levels to specific target cells or tissues. MEDI-579 is effective in a mouse model of diabetic kidney disease47 – a 
model demonstrated to be dependent upon the protease-inhibitory activity of PAI-1 alone48. The data presented 
here demonstrates that this protease-inhibitory function of PAI-1 is also fundamental in a mouse model of lupus 
nephritis.
Further mechanistic characterisation of MEDI-579 will build understanding of the specific role of PAI-1 in 
a variety of disease settings and may have implications for future design of drugs to this therapeutically relevant 
serpin.
Materials and Methods
All methods were carried out in accordance with relevant guidelines and regulations.
Isolation of anti-PAI-1 antibody. PAI-1 antigens were immobilised at 10 µg/ml on Amino Immobiliser 
plates (Nunc). PAI-1-specific scFvs were isolated from large scFv human antibody library after two rounds of 
selection essentially as described previously26.
ID29 ESRF
Data collection
Space group P21
Cell dimensions
  a, b, c (Å)
90.2
89.6
249.7
  a, b, g (°)
90.0
99.3
90.0
  Osc./# frames 0.2/1100
Wavelength 0.976
Resolution (Å) 15–2.9 (3.1–2.9)
Rsym or Rmerge 0.095 (0.47)
I/sI 4.8 (1.6)
Completeness (%) 98.9 (99.1)
Redundancy 4.4 (4.4)
Refinement
Resolution (Å) 2.9
No. reflections 86268
Rwork/Rfree 0.22/0.24
No. atoms
  Protein 24572
  Ligand/ion —
  Water 46
B-factors
  Protein 63.1
  Ligand/ion —
  Water 41.6
R.m.s deviations
  Bond lengths (Å) 0.010
  Bond angles (°) 1.12
Table 2. Data and refinement statistics.
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Figure 5. Crystal structure of MEDI-579 Fab/PAI-1 complex. (a) A ribbon diagram of a representative 
structure of the Fab-PAI-1 complex is show. MEDI-579 Fab (heavy chain in green, light chain in cyan) binds 
in a ‘protease-like’ manner, interacting with the RCL (yellow) and adjacent sites. (b) A surface representation 
of the top of PAI-1 with the RCL in yellow and the contact regions of the heavy and light chains coloured green 
and cyan, respectively, illustrates the footprint of the Fab on PAI-1. (c) The same ribbon depiction of the Fab/
PAI-1 complex with the position of uPA from 3pb17 illustrates the overlap of the binding sites. The reported 
vitronectin binding site on PAI-1 is indicated by a black circle. (d) The surface of the top of PAI-1 is coloured as 
in panel (b), but with the uPA footprint in magenta.
VH chaina Residueb
CDR2 Gly 50, Iso 51, Iso 52, Phe 54, Thr 56, Ala 57, Asn 58
CDR3 Glu 95, Arg 97, Trp 99, Leu 100, Glu 100a, Gly 100b
VL chaina
CDR1 Tyr 30, His 31, Asn 32*
CDR2 Lys 50
FW3/outer loop Arg 66*, Ser 67, Gly 68
CDR3 Tyr 91, Ser 92, Asn 93, Tyr 94, Leu 96
Table 3. MEDI-579 paratope residues. Residues within 4.0 Å of PAI-1 are listed and categorised by Kabat 
definition. Residues involved in H-bonding networks are highlighted in underline. Residues that form salt-
bridges with PAI-1 are highlighted in bold. *Indicates residues introduced during affinity maturation.
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Antibody optimisation by ribosome display. A ribosome-display scFv library was created by random 
mutagenesis using the Diversify™ PCR Random Mutagenesis Kit (BD Biosciences). The assembled scFv library 
with gene III tether was expressed in vitro using the RiboMAX™ Large Scale RNA Production System (T7) 
(Promega), following the manufacturers protocol, and an E.coli- based prokaryotic cell-free translation system. 
The scFv antibody-ribosome-mRNA (ARM) complexes were incubated in solution with biotinlyated active or 
mutant human PAI-1 as described previously49.
PAI-1/tPA competition binding assays. Maxisorp plates (Nunc) were coated with 0.5 µg/ml human or 
rat tPA. Wells were washed PBS + 0.05% (v/v) Tween-20 and blocked with PBS + 3% (w/v) autoclaved dried milk 
protein. To each well, 25 µl of crude periplasmic scFv and 25 µl of biotinylated human (2 nM) or rat (3 nM) PAI-1 
was added and allowed to equilibrate. Binding of PAI-1 was detected using streptavidin-Europium and DELFIA® 
assay conditions as per manufacturer’s instructions (Perkin Elmer).
PAI-1: Vitronectin Binding Assay. Human monomeric vitronectin (Molecular Innovations; MI, US) was 
coated onto 96 well Maxisorp plates (Nunc) at 0.15 µg/ml in PBS w/o Ca2+ and Mg2+ (Gibco). After one hour at 
room temperature wells were washed three times with PBS + 0.05% (v/v) Tween-20 (PBS-T) and blocked with 
PBS + 3% (w/v) skimmed milk powder for a further hour. To each sample well, biotinylated human active PAI-1 
(0.5 nM) plus a dilution series of either MEDI-579, 33B08 IgG or an irrelevant isotype-matched IgG control 
(CAT002 hIgG1κ) pre-mixed at room temperature in PBS + 1% (w/v) skimmed milk powder, was added. Plates 
were incubated for two hours at room temperature and washed three times with PBS-T. Streptavidin-Europium 
and DELFIA® assay conditions were followed as per manufacturer’s instructions (Perkin Elmer) to detect bioti-
nylated PAI-1/vitronectin complexes. Plates were read on an EnVision plate reader (Perkin Elmer) using a 
Europium DELFIA® detection protocol.
In vitro pharmacology assay. Normal human lung fibroblasts (NHLF) or mouse MLg lung fibroblast 
cells were plated (~20000/well, 96 well format; Lonza, Basel, Switzerland) and stimulated with rhTGFβ (100 
pM; R&D Systems, Abingdon, UK) for 18 h to induce the expression of PAI-1. Following washing of cells with 
HBSS, plasmin generation was then measured by incubation of the cells in phenol red-free HBSS with human 
lysine-plasminogen (5 μg/ml; Technoclone, Vienna, Austria) and the chromogenic plasmin substrate S2251 
(0.2 mM; Chromogenix, Milan, Italy) in the presence or absence of MEDI-579. An irrelevant isotype-matched 
IgG control (CAT002 hIgG1κ) was included in the NHLF experiments. An increase in absorbance at 405 nm at 
37 °C was then followed for up to 3 h.
Affinity determination. Surface plasmon resonance measurements using a BIAcore T100 (GE Healthcare 
Life Sciences) were performed essentially as described by Karlsson et al.50. In brief, antibodies were coupled to 
CM3 sensorchips using an amine coupling kit (GE Healthcare Life Sciences) at a surface density of approximately 
500 RU and a serial dilution (between 6.25 nM and 25 pM) of glycosylated human PAI-1 (and rat PAI-1 (both 
Molecular Innovations) in HBS-EP + (GE Healthcare Life Sciences) was passed over the sensorchip surface. The 
resulting sensorgrams were evaluated using the Biacore T100 Evaluation software (version 2.0.3, GE Healthcare 
Life Sciences) to provide kinetic data.
Crystallisation and structural determination of the MEDI-579:PAI-1 complex. MEDI-579 IgG1 
was digested in a solution containing 30 mM DL-cysteine hydrochloride dissolved in PBS (Gibco) plus 1 mg per 
100 mg IgG of papain from papaya latex (Sigma). The digest was terminated after 4.5 hours by the addition of 
0.5 M iodoacetamide (Sigma) to give 50 mM iodoacetamide in the final digest mixture. MEDI-579 Fab was puri-
fied using Q Sepharose (GE Healthcare), buffer exchanged into PBS (Gibco) pH 7.2 and concentrated to 10 mg/
ml. Purified protein of a stable quadruple mutant of PAI-151 was obtained from Jim Huntington, University of 
Cambridge, and produced according to the protocol referred to in Zhou et al.9. MEDI-579 Fab and PAI-1 were 
mixed at a 1:1 ratio, followed by buffer exchange into 15 mM ammonium acetate pH 7.4 and concentrated to a 
final protein concentration of 3–9 mg/ml. Crystals were grown from hanging drops equilibrated against a solution 
of 8–10% PEG 8000, 0.2 M LiCl and 20% ethylene glycol, then harvested and flash frozen. The initial screen-
ing for anisotropically diffracting and non-twinned crystals was carried out at the beamline 911:2 at the MAX 
IV Laboratory. Crystals were stored in preparation for data collection at the European Synchrotron Radiation 
Facility in Grenoble. A second data set to 2.9 Å, used for the final refinement, was collected at beamline ID29 
(wavelength of 0.976). Data were processed with MOSFLM52 and scaled with SCALA from the CCP4 suite53. The 
structure was determined by molecular replacement using the MOLREP54. Search models were obtained from a 
crystal structure of PAI-1 stability mutant (PDB code 4g8r)21 and a crystal structure of a Fab (PDB code 1aqk)55. 
Manual rebuilding of the model, which has four copies of a 1:1 complex of PAI-1 and Fab, was performed using 
the model-building program COOT56. The model was refined to convergence using Autobuster57. In the final 
model 95% of the residues were in favoured regions of the Ramachandran plot, with 4% in additional allowed 
regions.
Mouse lupus nephritis model. All procedures were performed in accordance with federal, state and 
Institutional guidelines in an AAALAC-accredited facility and were approved by the MedImmune Institutional 
Animal Care and Use Committee.
On day 0, mice were injected intravenously (lateral tail vein) with 0.3 × 1010 viral particles of either Ad Null 
(empty vector control) or Adenovirus-interferon-alpha (Adv-IFN) in 0.1 M phosphate buffered saline (PBS) pH 
7.2 (Gibco). Twice weekly dosing of MEDI-579 (1 mg/kg or 10 mg/kg; or antibody control, 10 mg/kg, intraperi-
toneally) began immediately following adenovirus delivery on day 0 and continued throughout the course of the 
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study. Mice were placed in metabolic cages once weekly in order to collect 24 hour urine samples. These urine 
samples were frozen and sent to AniLytics (Gaithersburg, MD) for chemistry analysis; total protein, creatinine 
and sodium. For the single dose pharmacodynamic assessment, NZBxNZW/F1 mice that had a dipstick reading 
of greater than 1 + (Chemstrip 2 GP, Roche, Indianapolis IN) at four weeks post-Adv-IFN infection, received a 
single dose of MEDI-579 (10 mg/kg; or antibody control, 10 mg/kg, intraperitoneally). Mice were terminated 
48 hours following administration and MEDI-579; active PAI-1 and active plasmin were measured in plasma.
Assessment of Active PAI-1 and Plasmin. Citrated plasma was collected by collecting whole blood into 
Eppendorf tubes containing 3.2% sodium citrate (1/10 the total sample volume). The blood was then centrifuged, 
plasma was drawn off, put into a clean Eppendorf tube and centrifuged again, samples were then frozen until 
assayed. Right kidneys collected, halved and frozen in liquid nitrogen until homogenised in ice-cold neutral 
lysis buffer (1% Triton X-100, 1 mM EDTA and protease inhibitors in PBS pH 7.2). The lysates were centrifuged 
and supernatants were transferred to new tubes and frozen until assayed. Mouse active PAI-1 and mouse active 
plasmin ELISA kits were purchased from Innovative Research (Nova, Michigan). Manufacturer instructions were 
followed for all assays.
Accession code. Coordinates and structure factors have been deposited in the Protein Data Bank, with 
accession code 6I8S.
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